National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013 (No. 6) (No. PB 29 of 2013) (Cth)

Case

PB 29 of 2013

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013
(No. 6)1


National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 21 May 2013

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

1          Name of Instrument

(1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013 (No. 6).

(2)        This Instrument may also be cited as PB 29 of 2013.

2          Commencement

This Instrument commences on 1 June 2013.

3          Amendment of National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).

Schedule 1     Amendments

  1. Schedule 1, entry for Ampicillin in each of the forms: Powder for injection 500 mg (as sodium); and Powder for injection 1 g (as sodium)

omit from the column headed “Responsible Person” for the brand “Ibimycin” (all instances):        TS          substitute:             WQ

  1. Schedule 1, entry for Carboplatin in each of the forms: Solution for I.V. injection 50 mg in 5 mL; Solution for I.V. injection 150 mg in 15 mL; and Solution for I.V. injection 450 mg in 45 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Carbaccord WQ MP See Note 3 See Note 3 1 D(100)
  1. Schedule 1, entry for Ciprofloxacin in the form Tablet 250 mg (as hydrochloride)

omit:

Profloxin HX MP NP C1143 C1431 C1432 C1572 C1573 14 0 14
  1. Schedule 1, entry for Citalopram in the form Tablet 10 mg (as hydrobromide)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Citalopram-GA GN MP NP C1211 28 5 28
  1. Schedule 1, entry for Citalopram in the form Tablet 40 mg (as hydrobromide)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Citalopram-GA GN MP NP C1211 28 5 28
  1. Schedule 1, entry for Epoetin Beta

omit:

Injection 20,000 units in 0.6 mL pre-filled syringe Injection NeoRecormon RO MP
See Note 1
C1957 C3334 12 5 6 D(100)
  1. Schedule 1, entry for Famciclovir in the form Tablet 500 mg [Maximum Quantity 56; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Auro-Famciclovir 500 DO MP NP C3626 C3627 C3628 C3629 P3626 P3627 P3628 P3629 56 5 56
  1. Schedule 1, entry for Felodipine in the form Tablet 2.5 mg (extended release)

omit from the column headed “Responsible Person” for the brand “Felodur ER 2.5 mg”:                                AL          substitute:                ZA

  1. Schedule 1, entry for Felodipine in the form Tablet 5 mg (extended release)

omit from the column headed “Responsible Person” for the brand “Felodur ER 5 mg”:                   AL          substitute:             ZA

  1. Schedule 1, entry for Felodipine in the form Tablet 10 mg (extended release)

omit from the column headed “Responsible Person” for the brand “Felodur ER 10 mg”:                 AL          substitute:             ZA

  1. Schedule 1, entry for Flucloxacillin in each of the forms: Powder for injection 500 mg (as sodium); and Powder for injection 1 g
    (as sodium)

omit from the column headed “Responsible Person” for the brand “Flubiclox” (all instances):      TS          substitute:             WQ

  1. Schedule 1, entry for Gabapentin in the form Tablet 600 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Gabapentin Aspen 600 FM MP NP C2664 100 5 100
  1. Schedule 1, entry for Gabapentin in the form Tablet 800 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Gabapentin Aspen 800 FM MP NP C2664 100 5 100
  1. Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride)

omit from the column headed “Responsible Person” for the brand “Gemcitabine Actavis”:             TA          substitute:             WQ

  1. Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride)

omit from the column headed “Responsible Person” for the brand “Gemcitabine Actavis”:             TA          substitute:             WQ

  1. Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 2 g (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Gemcitabine Actavis 2000 WQ MP See Note 3 See Note 3 1 D(100)
  1. Schedule 1, entry for Glucose Indicator―Blood

omit:

Test strips, 50 (TRUEbalance) For external use TRUEbalance NX MP NP 2 5 1
MP P3035 2 11 1
Test strips, 50 (TRUEresult) For external use TRUEresult NX MP NP 2 5 1
MP P3035 2 11 1
Test strips, 50 (TrueTrack) For external use TrueTrack NX MP NP 2 5 1
MP P3035 2 11 1
  1. Schedule 1, after entry for Glucose Indicator―Blood in the form Test strips, 100 (FreeStyle Optium)

insert in the columns in the order indicated:

Test strips, 100 (TRUEbalance) For external use TRUEbalance NX MP NP 1 5 1
MP P3035 1 11 1
Test strips, 100 (TRUEresult) For external use TRUEresult NX MP NP 1 5 1
MP P3035 1 11 1
Test strips, 100 (TRUEtrack) For external use TRUEtrack NX MP NP 1 5 1
MP P3035 1 11 1
  1. Schedule 1, entry for Lansoprazole

omit:

Lansoprazole Tablet 30 mg (orally disintegrating) Oral Zoton FasTabs PF MP NP C1177 C1337 C1533 P1177 28 1 28
MP NP C1177 C1337 C1533 P1337 P1533 28 5 28

substitute:

Lansoprazole Tablet 30 mg (orally disintegrating) Oral Zopral ODT AF MP NP C1177 C1337 C1533 P1177 28 1 28
Zoton FasTabs PF MP NP C1177 C1337 C1533 P1177 28 1 28
Zopral ODT AF MP NP C1177 C1337 C1533 P1337 P1533 28 5 28
Zoton FasTabs PF MP NP C1177 C1337 C1533 P1337 P1533 28 5 28
  1. Schedule 1, entry for Lansoprazole in the form Tablet 15 mg (orally disintegrating)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Zopral ODT AF MP NP C1337 C1533 28 5 28
  1. Schedule 1, entry for Naltrexone

omit from the column headed “Brand”:         Naltrexone generichealth             substitute:             Naltrexone GH

  1. Schedule 1, entry for Rosuvastatin

substitute:

Rosuvastatin Tablet 5 mg (as calcium) Oral APO-Rosuvastatin TX MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
Cavstat AF MP C1540 C3047 C4225 C4228 P1540 P4228 30 5 30
NP C1540 C4228 30 5 30
Chem mart Rosuvastatin CH MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
Crestor AP MP C1540 C3047 C4225 C4228 P1540 P4228 30 5 30
NP C1540 C4228 30 5 30
Rosuvastatin Actavis 5 WQ MP C1540 C3047 C4225 C4228 P1540 P4228 30 5 30
NP C1540 C4228 30 5 30
Rosuvastatin GH GQ MP C1540 C3047 C4225 C4228 P1540 P4228 30 5 30
NP C1540 C4228 30 5 30
Rosuvastatin RBX RA MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
Rosuvastatin Sandoz SZ MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
Terry White Chemists Rosuvastatin TW MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
APO-Rosuvastatin TX MP C4225 C4228 P4225 30 11 30
Cavstat AF MP C1540 C3047 C4225 C4228 P3047 P4225 30 11 30
Chem mart Rosuvastatin CH MP C4225 C4228 P4225 30 11 30
Crestor AP MP C1540 C3047 C4225 C4228 P3047 P4225 30 11 30
Rosuvastatin Actavis 5 WQ MP C1540 C3047 C4225 C4228 P3047 P4225 30 11 30
Rosuvastatin GH GQ MP C1540 C3047 C4225 C4228 P3047 P4225 30 11 30
Rosuvastatin RBX RA MP C4225 C4228 P4225 30 11 30
Rosuvastatin Sandoz SZ MP C4225 C4228 P4225 30 11 30
Terry White Chemists Rosuvastatin TW MP C4225 C4228 P4225 30 11 30
Tablet 10 mg (as calcium) Oral APO-Rosuvastatin TX MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
Cavstat AF MP C1540 C3047 C4225 C4228 P1540 P4228 30 5 30
NP C1540 C4228 30 5 30
Chem mart Rosuvastatin CH MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
Crestor AP MP C1540 C3047 C4225 C4228 P1540 P4228 30 5 30
NP C1540 C4228 30 5 30
Rosuvastatin Actavis 10 WQ MP C1540 C3047 C4225 C4228 P1540 P4228 30 5 30
NP C1540 C4228 30 5 30
Rosuvastatin GH GQ MP C1540 C3047 C4225 C4228 P1540 P4228 30 5 30
NP C1540 C4228 30 5 30
Rosuvastatin RBX RA MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
Rosuvastatin Sandoz SZ MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
Terry White Chemists Rosuvastatin TW MP C4225 C4228 P4228 30 5 30
NP C4228 30 5 30
APO-Rosuvastatin TX MP C4225 C4228 P4225 30 11 30
Cavstat AF MP C1540 C3047 C4225 C4228 P3047 P4225 30 11 30
Chem mart Rosuvastatin CH MP C4225 C4228 P4225 30 11 30
Crestor AP MP C1540 C3047 C4225 C4228 P3047 P4225 30 11 30
Rosuvastatin Actavis 10 WQ MP C1540 C3047 C4225 C4228 P3047 P4225 30 11 30
Rosuvastatin GH GQ MP C1540 C3047 C4225 C4228 P3047 P4225 30 11 30
Rosuvastatin RBX RA MP C4225 C4228 P4225 30 11 30
Rosuvastatin Sandoz SZ MP C4225 C4228 P4225 30 11 30
Terry White Chemists Rosuvastatin TW MP C4225 C4228 P4225 30 11 30
Tablet 20 mg (as calcium) Oral APO-Rosuvastatin TX MP C4225 C4227 P4227 30 5 30
NP C4227 30 5 30
Cavstat AF MP C1540 C3047 C4225 C4227 P1540 P4227 30 5 30
NP C1540 C4227 30 5 30
Chem mart Rosuvastatin CH MP C4225 C4227 P4227 30 5 30
NP C4227 30 5 30
Crestor AP MP C1540 C3047 C4225 C4227 P1540 P4227 30 5 30
NP C1540 C4227 30 5 30
Rosuvastatin Actavis 20 WQ MP C1540 C3047 C4225 C4227 P1540 P4227 30 5 30
NP C1540 C4227 30 5 30
Rosuvastatin GH GQ MP C1540 C3047 C4225 C4227 P1540 P4227 30 5 30
NP C1540 C4227 30 5 30
Rosuvastatin RBX RA MP C4225 C4227 P4227 30 5 30
NP C4227 30 5 30
Rosuvastatin Sandoz SZ MP C4225 C4227 P4227 30 5 30
NP C4227 30 5 30
Terry White Chemists Rosuvastatin TW MP C4225 C4227 P4227 30 5 30
NP C4227 30 5 30
APO-Rosuvastatin TX MP C4225 C4227 P4225 30 11 30
Cavstat AF MP C1540 C3047 C4225 C4227 P3047 P4225 30 11 30
Chem mart Rosuvastatin CH MP C4225 C4227 P4225 30 11 30
Crestor AP MP C1540 C3047 C4225 C4227 P3047 P4225 30 11 30
Rosuvastatin Actavis 20 WQ MP C1540 C3047 C4225 C4227 P3047 P4225 30 11 30
Rosuvastatin GH GQ MP C1540 C3047 C4225 C4227 P3047 P4225 30 11 30
Rosuvastatin RBX RA MP C4225 C4227 P4225 30 11 30
Rosuvastatin Sandoz SZ MP C4225 C4227 P4225 30 11 30
Terry White Chemists Rosuvastatin TW MP C4225 C4227 P4225 30 11 30
Tablet 40 mg (as calcium) Oral APO-Rosuvastatin TX MP C4225 C4226 P4226 30 5 30
NP C4226 30 5 30
Cavstat AF MP C1540 C3047 C4225 C4226 P1540 P4226 30 5 30
NP C1540 C4226 30 5 30
Chem mart Rosuvastatin CH MP C4225 C4226 P4226 30 5 30
NP C4226 30 5 30
Crestor AP MP C1540 C3047 C4225 C4226 P1540 P4226 30 5 30
NP C1540 C4226 30 5 30
Rosuvastatin Actavis 40 WQ MP C1540 C3047 C4225 C4226 P1540 P4226 30 5 30
NP C1540 C4226 30 5 30
Rosuvastatin GH GQ MP C1540 C3047 C4225 C4226 P1540 P4226 30 5 30
NP C1540 C4226 30 5 30
Rosuvastatin RBX RA MP C4225 C4226 P4226 30 5 30
NP C4226 30 5 30
Rosuvastatin Sandoz SZ MP C4225 C4226 P4226 30 5 30
NP C4226 30 5 30
Terry White Chemists Rosuvastatin TW MP C4225 C4226 P4226 30 5 30
NP C4226 30 5 30
APO-Rosuvastatin TX MP C4225 C4226 P4225 30 11 30
Cavstat AF MP C1540 C3047 C4225 C4226 P3047 P4225 30 11 30
Chem mart Rosuvastatin CH MP C4225 C4226 P4225 30 11 30
Crestor AP MP C1540 C3047 C4225 C4226 P3047 P4225 30 11 30
Rosuvastatin Actavis 40 WQ MP C1540 C3047 C4225 C4226 P3047 P4225 30 11 30
Rosuvastatin GH GQ MP C1540 C3047 C4225 C4226 P3047 P4225 30 11 30
Rosuvastatin RBX RA MP C4225 C4226 P4225 30 11 30
Rosuvastatin Sandoz SZ MP C4225 C4226 P4225 30 11 30
Terry White Chemists Rosuvastatin TW MP C4225 C4226 P4225 30 11 30
  1. Schedule 1, entry for Temozolomide in the form Capsule 180 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Astromide WQ MP C1736 C1737 C2101 5 5 5
  1. Schedule 3, after details relevant to Responsible person code YT

insert:

ZA AstraZeneca Pty Ltd  54 009 682 311
  1. Schedule 4, Part 1, entry for Rosuvastatin

(a)insert in the column headed “Purposes Code” for the Circumstances Code “C1540”             P1540

(b)insert in the column headed “Purposes Code” for the Circumstances Code “C3047”             P3047

(c)insert in numerical order following existing text:

C4225 P4225

For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs

Patient must be receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements;
The treatment must not be prescribed for hypercholesterolaemia if the patient has heterozygous familial hypercholesterolaemia

C4226 P4226

For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs

The treatment must not be prescribed for hypercholesterolaemia if the patient has heterozygous familial hypercholesterolaemia

C4227 P4227

For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs

The treatment must not be prescribed for hypercholesterolaemia if the patient has heterozygous familial hypercholesterolaemia

C4228 P4228

For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs

The treatment must not be prescribed for hypercholesterolaemia if the patient has heterozygous familial hypercholesterolaemia

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.

See

Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0